Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation

Thrombosis Research

Volumn 107, Issue 1-2, 2002, Pages 7-11

  Gouin Thibault, I ^a   Arkam, R ^b   Nassiri, S ^b   De la Tourette, A ^b   Conard, J ^b   Horellou, M H ^b   Elalamy, I ^b   Samama, M M ^b  

^a HÔPITAL CHARLES FOIX   (France)

^b HÔTEL DIEU   (France)

Author keywords

DDI; F1+2; Factor V Leiden; G20210A prothrombin gene mutation; TAT; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DIDANOSINE; PROTHROMBIN; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PEPTIDE FRAGMENT; PEPTIDE HYDROLASE; PROTHROMBIN FRAGMENT 1.2;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOTE; HORMONAL THERAPY; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MUTATION; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; BLOOD; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; POINT MUTATION; RISK FACTOR; VEIN THROMBOSIS;

ADULT; ANTITHROMBIN III; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; POINT MUTATION; PROTHROMBIN; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0037101576     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00189-5     Document Type: Article

References (24)

1. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc. Natl. Acad. Sci. U. S. A. 90:1993;1004-1008.
2. Rees D.C., Cos M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
3. Zivelin A., Griffin J.H., Xu X., Pabinger I., Samama M., Conard J.et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 89(2):1997;397-402.
4. Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H.et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
5. Nicolaes G.A.F., Tans G., Thomassen M.C.L.G.D., Hemker H.C., Pabinger I., Varadi K.et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J. Biol. Chem. 270:1995;21158-21166.
6. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
7. Rosendaal F., Doggen C., Zivelin A., Arruda V., Aiach M., Siskovick D.et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb. Haemost. 79:1998;706-708.
8. Tripodi A., Manucci P.M. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin. Chem. 42:1996;664-669.
9. Zoller B., Holm J., Svensson P.J., Dahlbäck B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-rsistance) and/or inherited protein S deficiency. Thromb. Haemost. 75(2):1996;270-274.
10. Martinelli I., Bottasso B., Duca F., Faioni E., Manucci P.M. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb. Haemost. 75(5):1996;703-705.
11. Leroy-Matheron C., Levent M., Pignon J.M., Mendonça C., Gouault-Heilmann M. The 1691 G→A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb. Haemost. 75(1):1996;4-10.
12. Simioni P., Scarano L., Gavasso S., Sardella C., Girolami B., Scudeller A.et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br. J. Haematol. 92(2):1996;435-441.
13. Eichinger S., Weltermann A., Philipp K., Hafner E., Kaider A., Kittl E.M.et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb. Haemost. 82:1999;1232-1236.
14. Mercuri F., Giacomello R., Puglisi F., Colaone R., Fabbro D., Menegon M.G.et al. V. Factor Leiden increases plasma F1+2 levels both in normal and deep venous thrombosis subjects. Haematologica. 85(4):2000;386-389.
15. Lowe G.D., Rumley A., Woodward M., Reid E., Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample - associations with cardiovascular risk factors and coagulation variables. Thromb. Haemost. 81(16):1999 June;918-924.
16. de la Tourette A., Conard J., Cambus J.P., Horellou M.H., Elalamy I., Beguin S.et al. Thrombin generation in plasma of patients with the prothrombin gene G20210A variant and/or the factor V Leiden. Thromb. Haemost. 1999 August;. [(Supplement) abstract no. 866].
17. Kyrle P.A., Mannhalter C., Beguin S., Stumpflen A., Hirschl M., Welterman A.et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler. Thromb. Vasc. Biol. 18(8):1998 Aug;1287-1291.
18. Franco R.F., Trip M.D., ten Cate H., van den Ende A., Prins M.H., Kastelein J.J.et al. The 20210G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br. J. Haematol. 104(1):1999 Jan;50-54.
19. Bertina R.M. Molecular risk factors for thrombosis. Thromb. Haemost. 82(2):1999;601-609.
20. Palareti G., Legnani C., Cosmi B., Guazzaloca G., Pancani C., Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulant is stopped. Thromb. Haemost. 87:2002;7-12.
21. Andreescu A.C.M., Cushman M., Roseendaal F.R. D-dimer as a risk factor for deep vein thrombosis: the Leiden thrombophilia study. Thromb. Haemost. 87:2002;47-51.
22. Kyrle P.A., Eichinger S., Pabinger I., Stümpflen, Hirschl M., Blalonczyk C.et al. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb. Haemost. 77(5):1997;829-833.
23. Rosendaal F.R., Koster T., Vandenbroucke J.P., Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 85:1995;1504-1508.
24. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. N. Engl. J. Med. 344(16):2001;1222-1231.